Xryma plans to seek Euronext Paris listing within 12 months, launching a pre‑listing liquidity facility and price discovery process
Executive summary: Xryma Plc announced it intends to reapply for admission to Euronext Paris within the next twelve months, ahead of submitting a formal listing application subject to Euronext's approval, and has initiated a pre‑listing liquidity facility and price discovery process. The plan signals Xryma’s pursuit of additional capital and liquidity through a European exchange, which could affect its valuation and provide Euronext with another potential listing.
Who is involved: Xryma Plc (the issuing company), Euronext Paris (the exchange responsible for approving the admission)
Likely next: Xryma will prepare and submit its formal listing application to Euronext within the next 12 months; Euronext will then review the application according to its admission criteria and decide on approval.
Xryma Plc has disclosed its intention to reapply for admission to Euronext Paris sometime in the next twelve months, pending Euronext’s approval. Before filing the formal application, the company will establish a pre‑listing liquidity facility and begin a price discovery process. The move reflects Xryma’s effort to secure a venue for capital raising and increase its visibility among European investors.
Timeline
- — Xryma Plc : Pre-Listing Liquidity Facility and Price Discovery Process (PR Newswire)
- — Ipsen provides update on Phase III BOLD trial in biliary atresia (GlobeNewswire)
- — Codexis Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
Analysis — what this means
Likely next events
- Xryma to submit its formal listing application to Euronext within the next 12 months
- Euronext to evaluate and decide on Xryma's admission application
Sectors affected
- Capital markets
- Exchange listings
Sources
- Xryma Plc : Pre-Listing Liquidity Facility and Price Discovery Process — PR Newswire
- Codexis Announces Pricing of Public Offering of Common Stock — GlobeNewswire
- Ipsen provides update on Phase III BOLD trial in biliary atresia — GlobeNewswire
Related cases
- Xryma Plc intends to pursue a Euronext Paris listing within the next 12 months after establishing a pre‑listing liquidity facility and price‑discovery process
- Xryma Plc gains Euronext Paris listing approval, paving the way for its cross‑border open‑banking expansion
- Xryma Plc gains approval to list on Euronext Paris, opening access to European capital markets